The PPARα is mainly expressed in the liver and other organs in the body and functions to control fatty acid degradation and glucose homeostasis by inducing the expression of downstream genes, such as the CPT-1 and MCAD [31, 32]. Actually, Saroglitazar, a novel PPARα agonist, has been demonstrated to ameliorate lipid and glucose metabolism in NAFLD patients [33–36]. Here, ACADM is linked to metabolic dysfunction-associated steatotic liver disease.